Premium
BKV‐specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA‐haploidentical haematopoietic cell transplantation
Author(s) -
Pello Oscar M.,
Innes Andrew J.,
Bradshaw Anne,
Finn SallyAnne,
Uddin Shab,
Bray Emma,
Olavarria Eduardo,
Apperley Jane F.,
Pavlů Jiří
Publication year - 2017
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12848
Subject(s) - bk virus , human leukocyte antigen , hemorrhagic cystitis , immunology , medicine , transplantation , refractory (planetary science) , adoptive cell transfer , complication , haematopoiesis , hematopoietic stem cell transplantation , immune system , t cell , stem cell , antigen , biology , kidney transplantation , genetics , astrobiology
Background Haemorrhagic cystitis caused by BK virus ( BKV ) is a known complication of allogeneic haematopoietic cell transplantation ( HCT ) and is relatively common following HLA‐haploidentical transplantation. Adoptive immunotransfer of virus‐specific T cells from the donor is a promising therapeutic approach, although production of these cells is challenging, particularly when dealing with low‐frequency T cells such as BKV ‐specific T cells. Case report Here, we present a patient who, following haploidentical HCT , developed severe BKV haemorrhagic cystitis, resistant to standard therapy. He responded well to adoptive transfer of donor cells enriched in BKV ‐specific T cells using the new second‐generation Clini MACS Prodigy and the Cytokine Capture System from Miltenyi Biotec. Treatment led to full resolution of both the symptoms and viraemia without unwanted complications. Conclusion Our observations suggest that use of products enriched with BKV ‐specific T cells generated using this system is safe and efficient in HLA‐haploidentical HCT where BKV cystitis can be a serious complication.